drugset / Trial / NCT02504320
Phase 1, Febuxostat XR Relative Bioavailability Study
RandomizedCrossoverOpen-labelBasic science
Summary
This study will assess the relative bioavailability, safety and tolerability following administration of 80 mg single oral doses of 4 febuxostat extended release (XR) formulations.
Timeline
- Start
- 2015-08
- Primary completion
- 2015-09
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Febuxostat | Small molecule | 80 mg | Oral |
Indications
No indication recorded.